OBJECTIVE: It has been suggested that both endogenous reproductive hormones and hormone therapy may play a protective role against coronary artery disease (CAD). However, recent clinical trials have failed to demonstrate the benefit of a variety of forms of hormone therapy. The observational data on the role of endogenous reproductive hormones, using surrogate measures such as number of birth, age at menarche, and age at menopause are inconsistent. In addition, the longer-term associations have not been evaluated. The aim of this study was to evaluate the relationships between detailed measurements of endogenous and exogenous estrogen exposure time with angiographic CAD and major adverse cardiovascular events. METHODS: We assessed total estrogen exposure time, quantitative CAD by a core angiography laboratory, and prospectively measured major adverse cardiovascular events in 646 postmenopausal women undergoing coronary angiography for evaluation for suspected ischemia in the Women's Ischemia Syndrome Evaluation (WISE) study. RESULTS: Timing of postmenopausal exogenous hormone therapy (HT) use was associated with reduced CAD. Two summarized total estrogen time scores (TET and sTET) were not related to angiographic CAD after accounting for HT use. In addition, these scores were not related to cardiovascular events over a median of 6.0 years of follow-up. CONCLUSIONS: There was no independent relation of estrogen exposure time to angiographic CAD or major adverse cardiovascular events in a contemporary cohort of postmenopausal women evaluated for suspected ischemia. Our results suggest that the paradigm of estrogen protection from CAD in women may be more complex than estrogen exposure duration alone.
OBJECTIVE: It has been suggested that both endogenous reproductive hormones and hormone therapy may play a protective role against coronary artery disease (CAD). However, recent clinical trials have failed to demonstrate the benefit of a variety of forms of hormone therapy. The observational data on the role of endogenous reproductive hormones, using surrogate measures such as number of birth, age at menarche, and age at menopause are inconsistent. In addition, the longer-term associations have not been evaluated. The aim of this study was to evaluate the relationships between detailed measurements of endogenous and exogenous estrogen exposure time with angiographic CAD and major adverse cardiovascular events. METHODS: We assessed total estrogen exposure time, quantitative CAD by a core angiography laboratory, and prospectively measured major adverse cardiovascular events in 646 postmenopausal women undergoing coronary angiography for evaluation for suspected ischemia in the Women's Ischemia Syndrome Evaluation (WISE) study. RESULTS: Timing of postmenopausal exogenous hormone therapy (HT) use was associated with reduced CAD. Two summarized total estrogen time scores (TET and sTET) were not related to angiographic CAD after accounting for HT use. In addition, these scores were not related to cardiovascular events over a median of 6.0 years of follow-up. CONCLUSIONS: There was no independent relation of estrogen exposure time to angiographic CAD or major adverse cardiovascular events in a contemporary cohort of postmenopausal women evaluated for suspected ischemia. Our results suggest that the paradigm of estrogen protection from CAD in women may be more complex than estrogen exposure duration alone.
Authors: B L Sharaf; C J Pepine; R A Kerensky; S E Reis; N Reichek; W J Rogers; G Sopko; S F Kelsey; R Holubkov; M Olson; N J Miele; D O Williams; C N Merz Journal: Am J Cardiol Date: 2001-04-15 Impact factor: 2.778
Authors: D M Herrington; D M Reboussin; K B Brosnihan; P C Sharp; S A Shumaker; T E Snyder; C D Furberg; G J Kowalchuk; T D Stuckey; W J Rogers; D H Givens; D Waters Journal: N Engl J Med Date: 2000-08-24 Impact factor: 91.245
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Helen S Kok; Kristel M van Asselt; Yvonne T van der Schouw; Ingeborg van der Tweel; Petra H M Peeters; Peter W F Wilson; Peter L Pearson; Diederick E Grobbee Journal: J Am Coll Cardiol Date: 2006-04-24 Impact factor: 24.094
Authors: C Noel Bairey Merz; B Delia Johnson; Sarah Berga; Glenn Braunstein; Steven E Reis; Vera Bittner Journal: Fertil Steril Date: 2006-04-05 Impact factor: 7.329
Authors: B Delia Johnson; C Noel Bairey Merz; Glenn D Braunstein; Sarah L Berga; Vera Bittner; T Keta Hodgson; Gretchen L Gierach; Steven E Reis; Diane A Vido; Barry L Sharaf; Karen M Smith; George Sopko; Sheryl F Kelsey Journal: J Womens Health (Larchmt) Date: 2004-10 Impact factor: 2.681
Authors: Judith Hsia; Robert D Langer; Joann E Manson; Lewis Kuller; Karen C Johnson; Susan L Hendrix; Mary Pettinger; Susan R Heckbert; Nancy Greep; Sybil Crawford; Charles B Eaton; John B Kostis; Pat Caralis; Ross Prentice Journal: Arch Intern Med Date: 2006-02-13
Authors: Raúl López-Grueso; Juan Gambini; Kheira M Abdelaziz; Daniel Monleón; Ana Díaz; Marya El Alami; Vicent Bonet-Costa; Consuelo Borrás; José Viña Journal: Antioxid Redox Signal Date: 2013-07-20 Impact factor: 8.401
Authors: S Mitchell Harman; Eric Vittinghoff; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Rogerio A Lobo; George R Merriam; Virginia M Miller; Frederick Naftolin; Lubna Pal; Nanette Santoro; Hugh S Taylor; Dennis M Black Journal: Am J Med Date: 2011-03 Impact factor: 4.965
Authors: Lili Barsky; Chrisandra Shufelt; Marie Lauzon; B Delia Johnson; Sarah L Berga; Glenn Braunstein; Vera Bittner; Leslee Shaw; Steven Reis; Eileen Handberg; Carl J Pepine; C Noel Bairey Merz Journal: J Womens Health (Larchmt) Date: 2021-01-21 Impact factor: 3.017
Authors: Julie J Lee; Galen Cook-Wiens; B Delia Johnson; Glenn D Braunstein; Sarah L Berga; Frank Z Stanczyk; Carl J Pepine; C Noel Bairey Merz; Chrisandra L Shufelt Journal: J Am Heart Assoc Date: 2019-06-05 Impact factor: 6.106